The Effect of Magnesium Oxide Nanoparticle Supplementation (MgO NPS) on Fetuin-A Gene Expression and Insulin Resistance in Rats with Type 2 Diabetes
| Author | Atousa Nikbakht Sheibani | en |
| Author | Mandana Gholami | en |
| Author | Sahar Ghareh | en |
| Author | Farshad Ghazalian | en |
| Orcid | Atousa Nikbakht Sheibani [0009-0003-1473-9551] | en |
| Orcid | Mandana Gholami [0000-0001-8960-4123] | en |
| Orcid | Sahar Ghareh [0000-0002-9213-1280] | en |
| Orcid | Farshad Ghazalian [0000-0002-5805-0559] | en |
| Issued Date | 2026-04-30 | en |
| Abstract | Background: Fetuin-A is a liver-derived hepatokine and a major contributor to insulin resistance in type 2 diabetes mellitus (T2DM). Individuals with T2DM frequently have low magnesium levels, which are associated with impaired metabolic health; however, standard magnesium supplements have shown variable therapeutic efficacy. Objectives: This study aimed to evaluate the effects of magnesium oxide nanoparticle supplementation (MgO NPS) on hepatic Fetuin-A mRNA expression and insulin resistance parameters in an experimental rat model of T2DM. Methods: A total of 24 male Wistar rats were equally allocated to three experimental groups (n = 8 per group): healthy control (HC), diabetic control (DC), and diabetic rats receiving MgO NPS (DS) at a daily dose of 300 mg/kg by oral gavage for 8 weeks. Diabetes was induced by intraperitoneal administration of nicotinamide (110 mg/kg), followed by streptozotocin (60 mg/kg). Results: Diabetic rats exhibited significantly higher fetuin-A expression and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) values than healthy controls (P < 0.001). MgO NPS significantly reduced both fetuin-A gene expression (1.05 ± 0.10 vs. 1.61 ± 0.16, P < 0.001) and HOMA-IR (1.16 ± 0.16 vs. 1.65 ± 0.25, P = 0.001) in diabetic rats. Conclusions: An 8-week course of MgO NPS significantly ameliorated insulin resistance in diabetic rats, with the downregulation of hepatic Fetuin-A expression as a plausible underlying mechanism. These findings suggest that nano-formulated magnesium may represent a promising candidate for future therapeutic approaches targeting hepatokine-driven insulin resistance in T2DM. | en |
| DOI | https://doi.org/10.5812/gct-170849 | en |
| URI | https://brieflands.com/journals/gct/articles/170849 | en |
| Keyword | Magnesium Oxide Nanoparticles | en |
| Keyword | fetuin-A | en |
| Keyword | Insulin Resistance | en |
| Keyword | Type 2 Diabetes Mellitus | en |
| Keyword | Hepatokines | en |
| Keyword | HOMA-IR | en |
| Publisher | Brieflands | en |
| Title | The Effect of Magnesium Oxide Nanoparticle Supplementation (MgO NPS) on Fetuin-A Gene Expression and Insulin Resistance in Rats with Type 2 Diabetes | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- gct-13-2-170849-publish-pdf.pdf
- Size:
- 402.36 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF